Abstracts tagged "lupus nephritis and rituximab"

Abstract Number: 2932 • 2015 ACR/ARHP Annual Meeting
A Retrospective Observational Study of Patients with Lupus Nephritis Treated with Rituximab in Combination with Cyclophosphamide
Nídia Oliveira¹, Mónica Ibañez², Natalia Ciang³ and David A. Isenberg⁴, ¹Internal Medicine Department, Hospital Pedro Hispano, Matosinhos, Portugal, London, United Kingdom, ²Rheumatology Department, Hospital Son Llàtzer, Palma de Mallorca, Spain, London, United Kingdom, ³Rheumatology Department, Queen Eliazbeth Hospital, Hong Kong, London, United Kingdom, ⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity. Many patients with refractory disease can not tolerate conventional immunosuppressive therapy. The aims of this…
Abstract Number: 588 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Rituximab In Patients With Refractory Lupus Nephritis, a Post-Hoc Analysis From Phase II Trial In Japan
Yoshiya Tanaka¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Nobuyuki Miyasaka⁴, Takayuki Sumida⁵, Tsuneyo Mimori⁶, Takao Koike⁷ and Kazuhiro Endo⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁷Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan, ⁸Clinical Development, Zenyaku Kogyo Co., Ltd., Tokyo, Japan
Background/Purpose: B-cell depletion therapy by rituximab has been reported to be useful for treatment of lupus nephritis (LN) in many observational uncontrolled studies, however, placebo-controlled…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].